Literature DB >> 28054150

Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.

Alessandra Fabbri1, Mara Cossa1, Angelica Sonzogni1, Mauro Papotti2, Luisella Righi2, Gaia Gatti2, Patrick Maisonneuve3, Barbara Valeri1, Ugo Pastorino4, Giuseppe Pelosi5,6,7.   

Abstract

Optimal histopathological analysis of biopsies from metastases of neuroendocrine tumor (NET) of the lung requires more than morphology only. Additional parameters such as Ki-67 labeling index are required for adequate diagnosis, but few studies have compared reproducibility of different counting protocols and modalities of reporting on biopsies of lung NET. We compared the results of four different manual counting techniques to establish Ki-67 LI. On 47 paired biopsies and surgical specimens from 22 typical carcinoids (TCs), 14 atypical carcinoids (ACs), six large cell neuroendocrine carcinomas (LCNECs), and five small cell carcinomas (SCCs) immunohistochemical staining of Ki-67 antigen was performed. We counted, in regions of highest nuclear staining (HSR), a full ×40-high-power field (diameter = 0.55 mm), 500 or 2000 cells, or 2 mm2 surface area, including the HSR or the entire biopsy fragment(s). Mitoses and necrosis were evaluated in an area of 2 mm2 or the entire biopsy fragment(s). Between the four counting methods, no differences in Ki-67 LI were observed. However, a Ki-67 LI higher than 5% was found in only four cases when in an HSR, 500 cells were counted (18%), five (23%) when in an HSR 2000 cells were counted, four (18%) when 2 mm2 were counted, and one (5%) TC case when the entire biopsy was counted. A 20% cutoff distinguished TC and AC from LCNEC and SCC with 100% specificity and sensitivity, while mitoses and necrosis failed to a large extent. Ki-67 LI in biopsy samples was concordant with that in resection specimens when 2000 cells, 2 mm2, or the entire biopsy fragment(s) were counted. Our results are important for clinical management of patients with metastases of a lung NET.

Entities:  

Keywords:  Atypical; Carcinoid; Carcinoma; Cell; Immunohistochemistry; KI-67 antigen; Large; Lung; Methodology; Neuroendocrine; Small; Tumors; Typical

Mesh:

Substances:

Year:  2017        PMID: 28054150     DOI: 10.1007/s00428-016-2062-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  73 in total

Review 1.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

2.  Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence?

Authors:  B Helpap; J Köllermann
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

3.  Classification of low-grade neuroendocrine tumors of midgut and unknown origin.

Authors:  Susanne Van Eeden; Pascal F H J Quaedvlieg; Babs G Taal; G Johan A Offerhaus; Cornelis B H W Lamers; Marie-Louise F Van Velthuysen
Journal:  Hum Pathol       Date:  2002-11       Impact factor: 3.466

Review 4.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

5.  Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.

Authors:  W D Travis; W Rush; D B Flieder; R Falk; M V Fleming; A A Gal; M N Koss
Journal:  Am J Surg Pathol       Date:  1998-08       Impact factor: 6.394

6.  Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms.

Authors:  Oscar Lin; Semra Olgac; Ileana Green; Maureen F Zakowski; David S Klimstra
Journal:  Am J Clin Pathol       Date:  2003-08       Impact factor: 2.493

7.  CD44 and OTP are strong prognostic markers for pulmonary carcinoids.

Authors:  Dorian R A Swarts; Mieke E R Henfling; Leander Van Neste; Robert-Jan van Suylen; Anne-Marie C Dingemans; Winand N M Dinjens; Annick Haesevoets; Martina Rudelius; Erik Thunnissen; Marco Volante; Wim Van Criekinge; Manon van Engeland; Frans C S Ramaekers; Ernst-Jan M Speel
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

Review 8.  Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice.

Authors:  Giuseppe Pelosi; Guido Rindi; William D Travis; Mauro Papotti
Journal:  J Thorac Oncol       Date:  2014-03       Impact factor: 15.609

9.  Proliferation Markers and Their Uses in the Study of Endocrine Tumors.

Authors:  Giuseppe Pelosi; Giuseppe Zamboni
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  19 in total

Review 1.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 2.  Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors.

Authors:  Dimitrios Moris; Ioannis Ntanasis-Stathopoulos; Diamantis I Tsilimigras; Mohamad A Adam; Chi-Fu Jeffrey Yang; David Harpole; Stamatios Theocharis
Journal:  Cancer Genomics Proteomics       Date:  2018 Mar-Apr       Impact factor: 4.069

Review 3.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 4.  Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms.

Authors:  Stefano La Rosa
Journal:  Endocr Pathol       Date:  2021-03-31       Impact factor: 3.943

Review 5.  Lung neuroendocrine tumors: A systematic literature review (Review).

Authors:  Cornel Savu; Alexandru Melinte; Camelia Diaconu; Ovidiu Stiru; Florentina Gherghiceanu; Ștefan Dragoș Octavian Tudorica; Oana Clementina Dumitrașcu; Angelica Bratu; Irina Balescu; Nicolae Bacalbasa
Journal:  Exp Ther Med       Date:  2021-12-28       Impact factor: 2.447

6.  Distinctive pathological and clinical features of lung carcinoids with high proliferation index.

Authors:  Caterina Marchiò; Gaia Gatti; Federica Massa; Luca Bertero; Pierluigi Filosso; Giuseppe Pelosi; Paola Cassoni; Marco Volante; Mauro Papotti
Journal:  Virchows Arch       Date:  2017-06-19       Impact factor: 4.064

7.  Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.

Authors:  Sanaz Taromi; Florentine Lewens; Ruza Arsenic; Dagmar Sedding; Jörg Sänger; Almut Kunze; Markus Möbs; Joana Benecke; Helma Freitag; Friederike Christen; Daniel Kaemmerer; Amelie Lupp; Mareike Heilmann; Hedwig Lammert; Claus-Peter Schneider; Karen Richter; Michael Hummel; Britta Siegmund; Meike Burger; Franziska Briest; Patricia Grabowski
Journal:  Oncotarget       Date:  2017-09-23

8.  Neuroendocrine carcinoma of esophageal and gastric cardia: clinicopathologic and immunohistochemistry study of 80 cases.

Authors:  Liangli Hong; Ying Zhang; Zhaoyong Liu
Journal:  Oncotarget       Date:  2017-12-22

9.  Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept.

Authors:  Giuseppe Pelosi; Federica Massa; Gaia Gatti; Luisella Righi; Marco Volante; Nadia Birocco; Patrick Maisonneuve; Angelica Sonzogni; Sergio Harari; Adriana Albini; Mauro Papotti
Journal:  Clin Pathol       Date:  2019-02-19

10.  Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients.

Authors:  Dan-Ming Wei; Wen-Jie Chen; Rong-Mei Meng; Na Zhao; Xiang-Yu Zhang; Dan-Yu Liao; Gang Chen
Journal:  Respir Res       Date:  2018-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.